Petauri Expands HEOR and Market Access Capabilities with Acquisition of Franklin Pharmaceutical Consulting

Acquisition strengthens Petauri's global expertise in generating, demonstrating, and communicating product value 

NASHVILLE, Tenn., Oct. 8, 2026 /PRNewswire/ -- Petauri, a purpose-built pharmaceutical services platform, today announced the acquisition of Franklin Pharmaceutical Consulting (FPC), a specialized health economics and outcomes research (HEOR), real-world evidence (RWE), and market access consultancy. The acquisition strengthens Petauri's ability to support life sciences companies in generating evidence, communicating product value, and navigating complex access and reimbursement decisions.

With decades of scientific and commercial leadership experience, FPC has provided strategic and tactical support for HEOR, medical, and market access teams across the product life cycle. FPC's expertise includes HEOR and RWE strategies, scientific payer-value communications, and payer-focused tools and dossiers that demonstrate the value of innovative medicines.

"Franklin Pharmaceutical Consulting is an outstanding addition to Petauri and a natural extension of our vision for Petauri Evidence," said Dan Renick, CEO of Petauri. "FPC brings deep expertise in translating HEOR and market access evidence into practical strategies and communications for a wide range of access decision-makers. Aligning FPC's strengths with our existing capabilities creates a more connected platform to support clients from evidence planning through commercialization and life cycle management."

"Our clients rely on us for senior-level expertise with solutions tailored to their evidence and access challenges," said Meg Franklin, PharmD, PhD, founder of FPC. "We are excited to join the Petauri team and expand the global capabilities available to our clients while maintaining the scientific rigor, collaboration, and hands-on partnership they value." Dr. Franklin will serve as President, Petauri Evidence US.

"Evidence has its greatest impact when it helps access decision-makers recognize a treatment's value," said Joette Gdovin, PhD, MPA, Partner at FPC, now EVP, Evidence & Value, Petauri Evidence US. "Together with Petauri, we will connect evidence generation, value communication, and market access strategies from the start, helping clients reduce barriers and secure access to meaningful treatment options for patients."

About Petauri

Petauri is a purpose-built pharmaceutical services platform based in Nashville, Tennessee. Founded by CEO Dan Renick in partnership with Oak Hill Capital, the platform is launching, acquiring, and combining best-in-class companies with recognized expertise in life sciences, health systems, scientific communications, and market access.

Since itsfounding in 2023, the platform has launched Petauri Advisors and acquired The Kinetix Group, the agencies of FORCE Communications, Mtech Access, Delta Hat, the agencies of the Brightly Network, Formulary Insights, and Artia Solutions, all now Powered by Petauri™. The legacy organizations now comprise Petauri's six business units: Petauri Advance, Petauri Advisors, Petauri Evidence, Petauri Kinect, Petauri MAx, and Artia Solutions. Oak Hill will invest more than $250 million of equity capital in this initiative from its latest fund (OHCP VI). The platform works with pharmaceutical and life sciences clients to improve patient outcomes by establishing the scientific, economic, humanistic, and societal value of medical advances.

From strategy to implementation, Petauri seamlessly supports these clients with a wide range of innovative solutions that speed patient access to life-changing care. For more information, please visit www.petauri.com.

Liz Gulino
[email protected]
(917) 410-1162

SOURCE Petauri